Your browser doesn't support javascript.
loading
Physical frailty deteriorates after a 5-day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study.
Verwaaijen, Emma J; van Hulst, Annelienke M; Hartman, Annelies; Pieters, Rob; Fiocco, Marta; Pluijm, Saskia M F; van Litsenburg, Raphaële R L; Grootenhuis, Martha A; van den Akker, Erica L T; van den Heuvel-Eibrink, Marry M.
Afiliação
  • Verwaaijen EJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van Hulst AM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Hartman A; Department of Pediatric Physiotherapy, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Pieters R; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Fiocco M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Pluijm SMF; Mathematical Institute Leiden University, Leiden, The Netherlands.
  • van Litsenburg RRL; Department of Biomedical Data Science, Section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.
  • Grootenhuis MA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van den Akker ELT; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Cancer Med ; 12(24): 22304-22315, 2023 12.
Article em En | MEDLINE | ID: mdl-38069550
ABSTRACT

BACKGROUND:

Dexamethasone is important in the treatment for pediatric acute lymphoblastic leukemia (ALL) but induces muscle atrophy with negative consequences for muscle mass, muscle strength, and functional abilities. The aim of this study was to establish the effect of a dexamethasone course on sarcopenia and physical frailty in children with ALL, and to explore prognostic factors.

METHODS:

Patients with ALL aged 3-18 years were included during maintenance therapy. Patients had a sarcopenia/frailty assessment on the first day of (T1) and on the day after (T2) a 5-day dexamethasone course. Sarcopenia was defined as low muscle strength in combination with low muscle mass. Prefrailty and frailty were defined as having two or ≥three of the following components, respectively low muscle mass, low muscle strength, fatigue, slow walking speed, and low physical activity. Chi-squared and paired t-tests were used to assess differences between T1 and T2. Logistic regression models were estimated to explore patient- and therapy-related prognostic factors for frailty on T2.

RESULTS:

We included 105 patients, 61% were boys. Median age was 5.3 years (range 3-18.8). At T1, sarcopenia, prefrailty, and frailty were observed in respectively 2.8%, 23.5%, and 4.2% of patients. At T2, the amount of patients with frailty had increased to 17.7% (p = 0.002), whereas the number of patients with sarcopenia and prefrailty remained similar. Higher ASMM (odds ratio [OR] 0.49, 95% CI 0.28-0.83), stronger handgrip strength (OR 0.41, 95% CI 0.22-0.77) and more physical activity minutes per day (OR 0.98, 95% CI 0.96-0.99) decreased the risk of frailty at T2. Slower walking performance (OR 2, 95% CI 1.2-3.39) increased the risk. Fatigue levels at T1 were not associated with frailty at T2.

CONCLUSION:

Physical frailty increased strikingly after a 5-days dexamethasone course in children with ALL. Children with poor physical state at start of the dexamethasone course were more likely to be frail after the course.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Sarcopenia / Fragilidade Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Sarcopenia / Fragilidade Idioma: En Ano de publicação: 2023 Tipo de documento: Article